Expert Panelists Program Goals Evaluating CV Risk in New Antidiabetic Therapies FDA Guidance EXAMINE and SAVORTIMI 53 EXAMINE New Analyses SAVORTIMI 53 Saxagliptin in Patients With T2D and History ofat Risk for CV Events ID: 723285
Download Presentation The PPT/PDF document "Emerging CV Outcomes Trial Results: What..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?Slide2
Expert PanelistsSlide3
Program GoalsSlide4
Evaluating CV Risk in New Antidiabetic TherapiesSlide5
FDA GuidanceSlide6Slide7Slide8Slide9
EXAMINE and SAVOR-TIMI 53Slide10Slide11
EXAMINE
New AnalysesSlide12
SAVOR-TIMI 53
Saxagliptin in
Patients With T2D and History of/at Risk for CV EventsSlide13
Advisory CommitteeSlide14
SAVOR-TIMI 53
Hospitalization for Heart FailureSlide15
TECOSSlide16
TECOSSitagliptin in Patients With T2D and Established CVDSlide17
TECOS
CV OutcomesSlide18
TECOS
Non-CV OutcomesSlide19
TECOS, EXAMINE, and SAVOR-TIMI 53
Patient PopulationSlide20
TECOS, EXAMINE, and SAVOR-TIMI 53
Hospitalization for Heart FailureSlide21
SGLT2 Inhibitors and Renal EffectsSlide22
SGLT2 Inhibitors
Renal EffectsSlide23
SGLT2 Inhibitors
Blood Pressure EffectsSlide24
SGLT2 Inhibitors and Antihypertensive Action
Proposed MOASlide25
SGLT2 Inhibitors and Natriuretic Effect
RCT of Dapagliflozin vs HCTZ vs PlaceboSlide26
CREDENCEEvaluation of Canagliflozin on Renal and CV Outcomes in Participants With Diabetic NephropathySlide27
SGLT2 Inhibitor + DPP-4 Inhibitor FDCSlide28
Empagliflozin + Linagliptin FDCEffect on HbA1cSlide29
Empagliflozin + Linagliptin FDCEffect on Body WeightSlide30
TECOS Sitagliptin in Patients With T2D and Established CVD Slide31
Empagliflozin + Linagliptin FDCEffect on HbA1c Is Not AdditiveSlide32
SGLT2 + DPP4 FDC
Potential Advantages/Disadvantages Slide33
AbbreviationsSlide34
ReferencesSlide35
References (cont)Slide36
References (cont)Slide37
References (cont)Slide38
References (cont)Slide39
References (cont)